Drug Trial Radar · NCT00252733
Diabetic Retinopathy Candesartan Trials
Last checked: Nov 20, 2026Latest source record: May 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,238
Actual
Start
Jun 2001
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Nov 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy. The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER). This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.
Conditions
- Type 1 Diabetes
Interventions
candesartan cilexetilDrug
32 mg once daily oral tablet given over 60 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.Time frame: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Herston, Australia
Research Site
Perth, Australia
Research Site
Odense, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.